08:13:00 EST Sat 09 Nov 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Mydecine Innovations Group Inc (2)
Symbol MYCO
Shares Issued 61,755,385
Close 2024-05-02 C$ 0.015
Market Cap C$ 926,331
Recent Sedar Documents

Mydecine Innovations receives MCTO

2024-05-02 19:42 ET - News Release

Mr. Joshua Bartch reports

MYDECINE RECEIVES MANAGEMENT CEASE TRADE ORDER

Mydecine Innovations Group Inc. received a temporary management cease trade order (MCTO) on April 26, 2024, under National Policy 12-203, Management Cease Trade Orders, from the British Columbia Securities Commission (BCSC) in connection with the company's filing of its audited annual financial statements and MD&A (management's discussion and analysis) for the financial year ended Dec. 31, 2023.

Pursuant to the MCTO, the chief executive officer and the chief financial officer of the company may not trade in securities of the company until such time as the company files its annual audited financial statements for the year ended Dec. 31, 2023, management's discussion and analysis, and related certifications (the required documents), and the BCSC revokes the MCTO. The MCTO does not affect the ability of shareholders to trade their securities.

The company's board of directors and management confirm that they are working expeditiously to file the required documents and confirm that since the company's news release dated May 1, 2024, there is no other material information respecting the company's affairs that has not been generally disclosed. The audited annual financial statements for Dec. 31, 2023, will include Dec. 31, 2022, restated comparatives as described in the April 25, 2024, news release.

Until the required documents have been filed, the company intends to continue to satisfy the provisions of the alternative information guidelines specified in NP 12-203 by issuing biweekly default status reports in the form of further news releases for so long as the company remains in default of the financial statement filing requirement.

About Mydecine Innovations Group Inc.

Mydecine is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Mydecine's dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world's leading specialists, the company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions. At the same time, Mydecine's approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with world-class scientific and regulatory expertise.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.